These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1972296)

  • 21. [Current medical therapies for Crohn's disease in Japan].
    Munakata A; Haga Y
    Nihon Geka Gakkai Zasshi; 1997 Apr; 98(4):406-11. PubMed ID: 9168493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
    Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
    Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Florent C; Cortot A; Quandale P; Sahmound T; Modigliani R; Sarfaty E; Valleur P; Dupas JL; Daurat M; Faucheron JL; Lerebours E; Michot F; Belaiche J; Jacquet N; Soulé JC; Rothman N; Gendre JP; Malafosse M
    Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):229-33. PubMed ID: 8724022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mesalazine in childhood inflammatory bowel disease.
    Barden L; Lipson A; Pert P; Walker-Smith JA
    Aliment Pharmacol Ther; 1989 Dec; 3(6):597-603. PubMed ID: 2577501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mesalazine and sulphasalazine for Crohn's disease: few indications, severe adverse reactions].
    Uittenbogaart SB; Klemt-Kropp M
    Ned Tijdschr Geneeskd; 2011; 155(48):A3842. PubMed ID: 22152414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE; Schraa CC
    Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrence of Crohn's disease in the neoterminal ileum after ileal resection: is prevention therapy possible?
    Rutgeerts P
    Neth J Med; 1994 Aug; 45(2):60-4. PubMed ID: 7936007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholestasis associated with mesalazine therapy in a patient with Crohn's disease.
    Stoschus B; Meybehm M; Spengler U; Scheurlen C; Sauerbruch T
    J Hepatol; 1997 Feb; 26(2):425-8. PubMed ID: 9059966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
    Maier K; Fischer C; Klotz U; Heinkel K
    Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
    Thomson AB
    Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission.
    Arber N; Odes HS; Fireman Z; Lavie A; Broide E; Bujanover Y; Becker S; Pomerantz I; Moshkowitz M; Patz J
    J Clin Gastroenterol; 1995 Apr; 20(3):203-6. PubMed ID: 7797827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
    Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
    Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease].
    Netzer P
    Schweiz Med Wochenschr; 1995 Dec; 125(50):2438-42. PubMed ID: 8553032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
    Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine.
    Das KM
    Postgrad Med; 1983 Dec; 74(6):141-8, 150-1. PubMed ID: 6139795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postoperative recurrence of Crohn's disease: pathogenesis and prevention.
    D'Haens GR; Rutgeerts PJ
    Acta Gastroenterol Belg; 1994; 57(5-6):311-3. PubMed ID: 7709700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second trial of mesalamine therapy in the treatment of active Crohn's disease.
    Singleton J
    Gastroenterology; 1994 Aug; 107(2):632-3. PubMed ID: 8039647
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.